☆ 4.6 Editorial Material

Re: Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients with Renal Cell Carcinoma Editorial Comment

JOURNAL OF UROLOGY (2012)

Get Full Text
Add to Collection

Journal

JOURNAL OF UROLOGY
Volume 188, Issue 6, Pages 2149-2150

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.juro.2012.08.170

Keywords

-

Categories

Urology & Nephrology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.